RVMD FY 2020 Earnings — Revolution Medicines, Inc. Revenue & Financial Results | Market Cap Arena

RVMDRevolution Medicines, Inc.

$20B

FY 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$43M-14.1% YoY

Gross Profit

$43M100.0% margin

Operating Income

-$111M-257.5% margin

Net Income

-$108M-251.6% margin

EPS (Diluted)

$-1.62

Cash Flow

Operating Cash Flow

-$100M

Free Cash Flow

-$103M

Stock-Based Comp.

$9M

Balance Sheet

Total Assets

$567M

Total Liabilities

$93M

Stockholders' Equity

$475M

Cash & Equivalents

$104M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$43M	$50M	-14.1%
Gross Profit	$43M	$50M	-14.1%
Operating Income	-$111M	-$54M	-104.5%
Net Income	-$108M	-$48M	-126.9%